leadf
logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm's drug developments sees growing market opportunities

Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.83 AUD

ASX:PAR
Market: ASX
Market Cap: $645.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Peninsula Energy continues in a strong financial position, debt free and...

Peninsula Energy (ASX: PEN) CEO Wayne Heili joined Steve Darling from Proactive to provide an update on the company that has seen a lot of milestones hit this year. Heili telling Proactive about their cash position, current activities at the Lance Project and what he sees as projected revenue...

1 day, 2 hours ago

2 min read